ArticleDiagnostics (Basel, Switzerland)2022

Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial.

Maaike Dotinga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.